Cells · 2024 · 13 citations · 29 references
Life SciencesImmunologyOncologyCancer ImmunologyInnate ImmunityTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesCytokines In Tumor ImmunityCytotoxic T Lymphocyte ResponsesT Cell Responses To TumorsAdjuvant DeliveryCd8 Positive T Cell ResponsesCd8 Positive T CellsCd8 T Cell ActivationInnate Antitumor ImmunityMitomycin C TreatmentMurine ModelsTissue-resident Macrophage Responses
Cancer-specific CD8+ cytotoxic T cells play important roles in preventing cancer growth, and IFN-γ, in addition to IL-12 and type I interferon, is critical for activating CD8+ cytotoxic T cells. We recently identified the capability of the amino-terminus region of dense granule protein 6 (GRA6Nt) of Toxoplasma gondii, an intracellular protozoan parasite, to activate IFN-γ production of microglia, a tissue-resident macrophage population. Therefore, in the present study, we examined whether recombinant GRA6Nt protein (rGRA6Nt) functions as an effective adjuvant to potently activate cancer-specific protective immunity using a murine model of MC38 colorectal cancer (CRC). When mice were immunized with non-replicable (either treated with mitomycin C or irradiated by X-ray) MC38 CRC cells in combination with rGRA6Nt adjuvant and received a challenge implantation of replication-capable MC38 tumor cells, those mice markedly inhibited the growth of the implanted tumors in association with a two-fold increase in CD8+ T cell density within the tumors. In addition, CD8+ T cells of the immunized mice secreted significantly increased amounts of granzyme B, a key mediator of the cytotoxic activity of CD8+ T cells, and IFN-γ in response to MC38 CRC cells in vitro when compared to the T cells from unimmunized mice. Notably, the protective effects of the immunization were specific to MC38 CRC cells, as the immunized mice did not exhibit a significantly inhibited growth of EL4 lymphoma tumors. These results indicate that rGRA6Nt is a novel and effective protein adjuvant when used in immunizations with non-replicable cancer cells to potently activate the protective immunity specifically against the cancer cells employed in the immunization.
29
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obéid, Antoine Tesnière, François Ghiringhelli et al. · Nature Medicine · 2006 · 3.1K citations
Medicine, Immunology, Oncology +14
Eiichi Sato, Sara H. Olson, Jiyoung Ahn et al. · Proceedings of the National Academy of Sciences · 2005 · 2.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Caetano Reis e Sousa, Sara Hieny, Tanya Scharton‐Kersten et al. · The Journal of Experimental Medicine · 1997 · 913 citations · Full text